Clinical Trials
47 trialsABBY
Abramson Cancer Center at Penn Medicine
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
I-SPY
QuantumLeap Healthcare Collaborative
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
FAIM
Royal Marsden NHS Foundation Trust
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Clinical and P
Beni-Suef University
CARABELA
Spanish Breast Cancer Research Group
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
MiRaDoR
MedSIR
VIOLET
Mario Negri Institute for Pharmacological Research
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Dana-Farber Cancer Institute
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
Fudan University
DISCORDANT
Danish Breast Cancer Cooperative Group
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
BRE-09
University of Illinois at Chicago
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
ARCHE
Nagoya City University
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
AURA
Japanese Foundation for Cancer Research
AMBRE
UNICANCER
ROYAL
Azienda Ospedaliero-Universitaria di Modena
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
BRAVE-Cyclin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
MINERVA
University of Ulm
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Neo-AGILE
Fondazione Oncotech
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
abemaSNF1/3
Fudan University
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
The Affiliated Hospital of Qingdao University
Rainbow
Fudan University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
CINDERELLA
Fudan University
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
University of California, Irvine
ORACLE-RIPA
National Taiwan University Hospital
T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
Academic and Community Cancer Research United
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Emory University
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Dana-Farber Cancer Institute
ABC-POP
Gustave Roussy, Cancer Campus, Grand Paris